Skip to main contentSkip to navigationSkip to search

Delivering better treatments

Camurus is committed to improving the lives of patients
with severe and chronic diseases

Read more


Latest news

Disease areas

Focus on severe and chronic diseases

Developing treatments for diseases within the central nervous system, rare diseases, endocrinology, oncology and supportive care

Learn more on disease areas


Upcoming events

See all events

  • 08 May

    Interim Report January-March 2024

    The interim report January-June is published on 8 May 2024.

    Add to calendar

  • 08 May

    Annual General Meeting 2024

    The Annual General Meeting in Camurus will be held on Wednesday, 8 May 2024 at 5:00 pm CET at Elite Hotel Ideon in Lund, Sweden.

    Add to calendar

  • 23 May

    SEB Small- & Midcap Seminar 2024

    Camurus’ President & CEO Fredrik Tiberg is presenting at this conference in Stockholm, 23 May. More information will follow closer to the event.

    Add to calendar

Latest financial report

Camurus Annual Report for 2023

28 March 2024

Go to report archive


Addressing important unmet medical needs

Learn about our products


Living with opioid dependence

Read Daniel's story

Annual General Meeting

Camurus’ Annual General Meeting 2024 will be held on Wednesday, 8 May 2024 at Elite Hotel Ideon in Lund, Sweden.

Registration is done via Euroclear no later than 2 May, 2024:
For more information see: Notice of Annual General Meeting 2024

See documents for Annual General Meeting 2024
See more information on Camurus' general meetings


Diversified pipeline with large potential

Camurus' innovative product candidates are designed to address important unmet medical needs, with the potential to make significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.

See pipeline


Sustainable solutions for a healthier world

Ensuring the long-term successful development of our business – for the benefit of patients, healthcare systems, employees and shareholders.

Learn more